Replay available

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Q3 2025 earnings conference call, held 2025-11-12. Replay captured from the company's public earnings webcast.

Wed, November 12, 2025 at 8:00 AMendedReplay
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Alex Braun

Head of Investor Relations

Dan O'Connell

Chief Executive Officer

Matt Zuga

Chief Financial Officer and Chief Business Officer

Dr. Jim Doherty

Chief Development Officer

Dr. Eric Siemers

Chief Medical Officer

Jason Zemanski

Analyst, Bank of America

Tom Schrader

Analyst, BTIG

Replay transcript excerpt

Good day, and welcome to the Acumen Farmer third quarter 2025 conference call and webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question, please press star 1-1. If your question hasn't been answered and you'd like to remove yourself from the queue, press star 1-1 again. As a reminder, this call may be recorded. I would now like to turn the call over to Alex Braun, head of investor relations. Please go ahead. Thanks, Michelle. Good morning, and welcome to the Acumen conference call to discuss our business update and financial results for the quarter ended September 30th, 2025. With me today are Dan O'Connell, our Chief Executive Officer, and Matt Zuga, our CFO and Chief Business Officer. Matt and Dan have some brief prepared remarks, and then we'll open the call for questions. Joining for the Q&A session, we also have Dr. Jim Doherty, our Chief Development Officer, and Dr. Eric Siemers, our Chief Medical Officer. Before we begin, we encourage listeners to go to the Investors section of the Acumen website to find our press release issue this morning that we'll discuss today. Please note that during today's conference call, we may make forward-looking statements within the meaning of the federal securities laws, including statements concerning our financial outlook and expected business plans. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Please see slide two of our corporate presentation, our press release issue this morning, and our most recent annual and quarterly reports, files of the SEC for important risk factors that could cause our actual...

More from Acumen Pharmaceuticals, Inc.